WO2007096151A3 - Composes organiques - Google Patents

Composes organiques Download PDF

Info

Publication number
WO2007096151A3
WO2007096151A3 PCT/EP2007/001508 EP2007001508W WO2007096151A3 WO 2007096151 A3 WO2007096151 A3 WO 2007096151A3 EP 2007001508 W EP2007001508 W EP 2007001508W WO 2007096151 A3 WO2007096151 A3 WO 2007096151A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
pulmonary hypertension
kinase
inhibitors
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/001508
Other languages
English (en)
Other versions
WO2007096151A2 (fr
Inventor
Christoph Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Publication of WO2007096151A2 publication Critical patent/WO2007096151A2/fr
Publication of WO2007096151A3 publication Critical patent/WO2007096151A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation d'un composé de formule A ou d'un dérivé pharmaceutiquement acceptable de celui-ci pour la fabrication d'un médicament destiné au traitement de l'hypertension pulmonaire. Dans la formule A, R1, R2, R5, R6, B, C, D et G possèdent les significations décrites dans la présente demande. La présente invention a également trait à des compositions pharmaceutiques contenant lesdits composés.
PCT/EP2007/001508 2006-02-23 2007-02-21 Composes organiques Ceased WO2007096151A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0603684.2A GB0603684D0 (en) 2006-02-23 2006-02-23 Organic compounds
GB0603684.2 2006-02-23

Publications (2)

Publication Number Publication Date
WO2007096151A2 WO2007096151A2 (fr) 2007-08-30
WO2007096151A3 true WO2007096151A3 (fr) 2007-11-01

Family

ID=36178660

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/001508 Ceased WO2007096151A2 (fr) 2006-02-23 2007-02-21 Composes organiques

Country Status (2)

Country Link
GB (1) GB0603684D0 (fr)
WO (1) WO2007096151A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014913A1 (fr) 2008-08-01 2010-02-04 Ventirx Pharmaceuticals, Inc. Formulations d'agoniste des récepteurs de type toll et leur utilisation
AU2009313392B2 (en) 2008-11-06 2016-05-05 Array Biopharma, Inc. Methods of synthesis of benzazepine derivatives
KR20170015566A (ko) 2008-11-10 2017-02-08 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
JP5603343B2 (ja) 2008-11-26 2014-10-08 アリーナ ファーマシューティカルズ， インコーポレイテッド 関連する障害を処置するために有用なプロスタサイクリン（ｐｇｉ２）受容体モジュレーターとしてのピラゾリル置換炭酸誘導体
ES2663222T3 (es) 2008-12-19 2018-04-11 Vertex Pharmaceuticals Incorporated Derivados de pirazina útiles como inhibidores de la quinasa ATR
CA2771609C (fr) 2009-08-18 2018-10-02 Ventirx Pharmaceuticals, Inc. Benzoazepines substituees comme modulateurs des recepteurs de type toll
EP2467380B1 (fr) 2009-08-18 2016-11-30 Ventirx Pharmaceuticals, Inc. Benzoazépines substituées comme modulateurs des récepteurs de type toll
JP2013526540A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
JP5856151B2 (ja) 2010-05-12 2016-02-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼ阻害剤として有用な２−アミノピリジン誘導体
JP2013529200A (ja) 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2013526539A (ja) 2010-05-12 2013-06-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用なピラジン
US9630956B2 (en) 2010-05-12 2017-04-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
CA2803802A1 (fr) 2010-06-23 2011-12-29 Vertex Pharmaceuticals Incorporated Derives de pyrrolo-pyrazine utiles en tant qu'inhibiteurs de l'atr kinase
JP2014510151A (ja) 2011-04-05 2014-04-24 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ（ｔｒａｋｉｎａｓｅ）阻害剤として有用なアミノピラジン化合物
WO2012178125A1 (fr) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Composés inhibiteurs de la kinase atr
WO2012178124A1 (fr) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de la kinase atr
EP2723745A1 (fr) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Composés utiles comme inhibiteurs de la kinase atr
SG10201606774UA (en) 2011-09-30 2016-10-28 Vertex Pharma Processes for making compounds useful as inhibitors of atr kinase
WO2013049859A1 (fr) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Traitement du cancer du pancréas et du cancer du poumon non à petites cellules avec des inhibiteurs de l'atr
KR20140084112A (ko) 2011-09-30 2014-07-04 버텍스 파마슈티칼스 인코포레이티드 Ａｔｒ 키나제의 억제제로서 유용한 화합물
WO2013049719A1 (fr) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Composés utiles en tant qu'inhibiteurs de kinase atr
US8853217B2 (en) 2011-09-30 2014-10-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071085A1 (fr) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Composés de pyrazine utiles comme inhibiteurs de kinase atr
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013071094A1 (fr) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de kinase atr
WO2013071088A1 (fr) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Composés utiles comme inhibiteurs de kinase atr
RU2625762C2 (ru) * 2012-03-20 2017-07-18 Новартис Аг Применение производной пиразола в лечении острых приступов хронической обструктивной болезни легких
CA2869309C (fr) 2012-04-05 2021-02-09 Vertex Pharmaceuticals Incorporated Composes utiles comme inhibiteurs d'atr kinase et therapies combinees les utilisant
US8999632B2 (en) 2012-10-04 2015-04-07 Vertex Pharmaceuticals Incorporated Method for measuring ATR inhibition mediated increases in DNA damage
US8912198B2 (en) 2012-10-16 2014-12-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
JP2016512815A (ja) 2013-03-15 2016-05-09 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
DK3077397T3 (da) 2013-12-06 2019-12-16 Vertex Pharma 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
PL3152212T3 (pl) 2014-06-05 2020-06-15 Vertex Pharmaceuticals Inc. Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
HK1258570A1 (zh) 2015-09-30 2019-11-15 Vertex Pharmaceuticals Inc. 使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
AU2016397046B2 (en) * 2016-03-08 2022-05-12 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of inflammatory conditions
BR112018067454A2 (pt) 2016-03-08 2019-01-15 Mereo Biopharma 1 Ltd regime de dosagem para o tratamento de exacerbações agudas de doença pulmonar obstrutiva crônica
WO2019071147A1 (fr) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. Inhibiteurs de la kinase p38 réduisant l'expression du gène dux4 et des gènes aval pour le traitement de la fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
HUE054266T2 (hu) 2017-12-11 2021-08-30 Mereo Biopharma 1 Ltd 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-N-ciklopropil-4-metilbenzamid alkalmazása krónikus obstruktív tüdõbetegség akut megjelenésének megelõzésében
AU2018382895B2 (en) 2017-12-11 2024-05-16 Mereo Biopharma 1 Limited Use of 3-(5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057101A1 (fr) * 1998-05-05 1999-11-11 F. Hoffmann-La Roche Ag Derives de pyrazole tenant lieu d'inhibiteurs de p.38 map kinase
WO2001021591A1 (fr) * 1999-09-22 2001-03-29 F. Hoffmann-La Roche Ag Derives pyrazole
WO2004016267A1 (fr) * 2002-08-14 2004-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Traitement anticoagulant et fibrinolytique a base d'inhibiteurs de p38 map kinase
WO2005009973A1 (fr) * 2003-06-26 2005-02-03 Novartis Ag Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons
WO2005018624A2 (fr) * 2003-08-22 2005-03-03 Boehringer Ingelheim Pharmaceuticals, Inc. Procedes pour traiter la bronchopneumopathie chronique obstructive et l'hypertension pulmonaire

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057101A1 (fr) * 1998-05-05 1999-11-11 F. Hoffmann-La Roche Ag Derives de pyrazole tenant lieu d'inhibiteurs de p.38 map kinase
WO2001021591A1 (fr) * 1999-09-22 2001-03-29 F. Hoffmann-La Roche Ag Derives pyrazole
WO2004016267A1 (fr) * 2002-08-14 2004-02-26 Boehringer Ingelheim Pharmaceuticals, Inc. Traitement anticoagulant et fibrinolytique a base d'inhibiteurs de p38 map kinase
WO2005009973A1 (fr) * 2003-06-26 2005-02-03 Novartis Ag Inhibiteurs de la kinase p38 a base d'heterocycles a 5 chainons
WO2005018624A2 (fr) * 2003-08-22 2005-03-03 Boehringer Ingelheim Pharmaceuticals, Inc. Procedes pour traiter la bronchopneumopathie chronique obstructive et l'hypertension pulmonaire

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LU JUN ET AL: "Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats.", THE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY DEC 2004, vol. 128, no. 6, December 2004 (2004-12-01), pages 850 - 859, XP004661334, ISSN: 0022-5223 *
WELSH ET AL: "p38 MAP kinase isoform activity and cell cycle regulators in the proliferative response of pulmonary and systemic artery fibroblasts to acute hypoxia", PULMONARY PHARMACOLOGY AND THERAPEUTICS, ACADEMIC PRESS, NEW YORK, NY, US, vol. 19, no. 2, April 2006 (2006-04-01), pages 128 - 138, XP005234602, ISSN: 1094-5539 *

Also Published As

Publication number Publication date
WO2007096151A2 (fr) 2007-08-30
GB0603684D0 (en) 2006-04-05

Similar Documents

Publication Publication Date Title
WO2007096151A3 (fr) Composes organiques
WO2009155121A3 (fr) Inhibiteurs de la pi3 kinase
WO2007148185A3 (fr) 3-amino-pyrrolidino-4-lactames substitués
WO2007135527A3 (fr) Composés de benzimidazolyle
WO2008027542A3 (fr) Composés d'isoindoline substituée en 5
WO2005075425A3 (fr) Derives de bisaryluree
WO2008013838A3 (fr) Dérivés de pyridizinone
WO2007082808A3 (fr) Thiazoles en tant qu'inhibiteurs de 11 beta-hsd1
WO2007027527A3 (fr) Composes d'isoindole-imide et compositions renfermant ceux-ci et procedes d'utilisation de ceux-ci
WO2009144555A8 (fr) Inhibiteurs de la pyrazolospirocétone acétyl-coa carboxylase
WO2009111700A3 (fr) Oxadiazoanthracènes pour le traitement du diabète
WO2006039718A3 (fr) Composes bicycliques azotes d'aryle et leurs procedes d'utilisation
WO2007060140A3 (fr) Inhibiteurs de diacylglycérol acyltransférase (dgat)
WO2007112014A3 (fr) Nouvelles combinaisons thérapeutiques pour le traitement de la dépression
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2007146856A3 (fr) Gamma lactames substitués utilisés en tant qu'agents thérapeutiques
WO2005115470A3 (fr) COMPOSITIONS PHARMACEUTIQUES CONTENANT DES DERIVES DE β-­CARBOLINE, ET LEUR UTILISATION POUR LE TRAITEMENT DES CANCERS
WO2008006795A3 (fr) Composés d'indole
WO2007020213A3 (fr) Derives de thiazolylpiperidines
WO2007056219A3 (fr) [(2,4-dioxo-1,4-dihydro-2h-quinazoline-3-yl)-phenyle]-5-chloro-thiophene-2-yl-sulfonylurees [4-(6-halo-7-substitutees)] et formes et procedes associes
WO2009041787A3 (fr) Composition pharmaceutique comprenant des inhibiteurs de molécule d'adhérence cellulaire isolée de piper nigrum pour la prévention et le traitement de maladies inflammatoires
WO2007103762A3 (fr) Compositions et procedes d'utilisation d'inhibiteurs de systemes de transport d'electrons
WO2007131907A3 (fr) Dérivés de 1h-indol-5-yl-pipérazin-1-yl-méthanone
WO2009038412A3 (fr) Composés inhibiteurs de la béta-sécrétase
TW200626158A (en) Naphthaline derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07722884

Country of ref document: EP

Kind code of ref document: A2